iSERA Lifesciences 143.90
+0.00 (+0.00%)

iSERA Lifesciences Share Price

143.90+0.00 (+0.00%)
+1331.84% past 1 Year

Corporate filings & documents

Announcements

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 - Administrative Warning Letter received from the Securities and Exchange Board of India (the SEBI).
1 week ago
Dissemination of Warning Letter of SEBI
1 week ago
Intimation for Newspaper Publication of Un-Audited Financial Results for the quarter and half year ended 30th September 2026 pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
2 weeks ago
Intimation for Newspaper Publication of Un-Audited Financial Results for the quarter and half year ended 30th September 2026 pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
2 weeks ago
We hereby submit the revised un-Audited Financial result for Half year ended September 2026 under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
2 weeks ago
We hereby submit the revised un-Audited Financial result for Half year ended September 2026 under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
2 weeks ago
We hereby submit that pursuant to Regulation 15(2) of SEBI (LODR) Regulations 2015 the compliance with the corporate governance provisions as specified in Regulations 17 18 19 20 21 22 23 24 25 26 27 and clause (b) to (i) of Sub Regulation (2) of Regulation 46 and Para C D and E of Schedule V shall not apply to the Company since the Paid-up Equity Share Capital and Net Worth as on 31st March 2026 is less than Rs. 10 Crore and Rs. 25 Crore respectively Accordingly the Company falls under the exemption criteria provided and is not required to comply with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.ed Financial Result for the quarter and half yearly ended September 2026
2 weeks ago
We hereby submit that pursuant to Regulation 15(2) of SEBI (LODR) Regulations 2015 the compliance with the corporate governance provisions as specified in Regulations 17 18 19 20 21 22 23 24 25 26 27 and clause (b) to (i) of Sub Regulation (2) of Regulation 46 and Para C D and E of Schedule V shall not apply to the Company since the Paid-up Equity Share Capital and Net Worth as on 31st March 2026 is less than Rs. 10 Crore and Rs. 25 Crore respectively Accordingly the Company falls under the exemption criteria provided and is not required to comply with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.ed Financial Result for the quarter and half yearly ended September 2026
2 weeks ago
We hereby submit the Un-Audited Financial Result for the quarter and half yearly ended September 2026
2 weeks ago
We hereby submit the Un-Audited Financial Result for the quarter and half yearly ended September 2026
2 weeks ago
Outcome of the Board Meeting held today on 4th November 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
2 weeks ago
Outcome of the Board Meeting held today on 4th November 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
2 weeks ago
Isera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 inter alia to consider and approve the Un-Audited Financial Results of the Company for the quarter and half year ended on September 30 2026
3 weeks ago
Isera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 inter alia to consider and approve the Un-Audited Financial Results of the Company for the quarter and half year ended on September 30 2026
3 weeks ago
We hereby submit the certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations 2018 for the quarter and half year Y ended September 30 2026.
1 month ago
We hereby submit the certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations 2018 for the quarter and half year Y ended September 30 2026.
1 month ago
Disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations 2015 - Continual Disclosure consequent to Preferential Allotment of Equity Shares on a Share Swap Basis
1 month ago
Disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations 2015 - Continual Disclosure consequent to Preferential Allotment of Equity Shares on a Share Swap Basis
1 month ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Archana Lonkar
1 month ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nandkumar Kadam
1 month ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dhairyasheel Yadav
1 month ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dhairyasheel Yadav
1 month ago
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sumeet Dhanraj Garad
1 month ago
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sumeet Dhanraj Garad
1 month ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Pratap Dadasaheb Deshmukh & PACs
1 month ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Pratap Dadasaheb Deshmukh & PACs
1 month ago
The Board of Directors of the Company at its meeting held today i.e. October 01 2026 has approved the allotment of 1 61 82 800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value of Rs. 10/- (Rupees Ten only) each at an issue price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty only) per share [including a share premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty only) per share] on a preferential basis by way of Share Swap at a ratio of 1:1 (i.e. one equity share of the Company for every one equity share of iSERA Biological Limited held by the allottee) to the following allottees belonging to the Promoter and Non-Promoter categories.
1 month ago
The Board of Directors of the Company at its meeting held today i.e. October 01 2026 has approved the allotment of 1 61 82 800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value of Rs. 10/- (Rupees Ten only) each at an issue price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty only) per share [including a share premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty only) per share] on a preferential basis by way of Share Swap at a ratio of 1:1 (i.e. one equity share of the Company for every one equity share of iSERA Biological Limited held by the allottee) to the following allottees belonging to the Promoter and Non-Promoter categories.
1 month ago
The Board of Directors of the Company at its meeting held today i.e. October 01 2026 has approved the allotment of 1 61 82 800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value of Rs. 10/- (Rupees Ten only) each at an issue price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty only) per share [including a share premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty only) per share] on a preferential basis by way of Share Swap at a ratio of 1:1 (i.e. one equity share of the Company for every one equity share of iSERA Biological Limited held by the allottee) to the following allottees belonging to the Promoter and Non-Promoter categories.
1 month ago
The Board of Directors of the Company at its meeting held today i.e. October 01 2026 has approved the allotment of 1 61 82 800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value of Rs. 10/- (Rupees Ten only) each at an issue price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty only) per share [including a share premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty only) per share] on a preferential basis by way of Share Swap at a ratio of 1:1 (i.e. one equity share of the Company for every one equity share of iSERA Biological Limited held by the allottee) to the following allottees belonging to the Promoter and Non-Promoter categories.
1 month ago
We are hereby submitting the Consolidated Scrutinizers Report on E-voting during Annual General Meeting of iSEAR Lifesciences Limited (Formerly Known as Covidh Technologies Limited held through Video Conferencing (VC)/Other Audio Visual Means (OAVM) on Tuesday 29th September 2026 at 3:00 P.M.
1 month ago
We are hereby submitting the Consolidated Scrutinizers Report on E-voting during Annual General Meeting of iSEAR Lifesciences Limited (Formerly Known as Covidh Technologies Limited held through Video Conferencing (VC)/Other Audio Visual Means (OAVM) on Tuesday 29th September 2026 at 3:00 P.M.
1 month ago
We hereby submit the proceeding of the 34th AGM
1 month ago
We hereby submit the proceeding of the 34th AGM
1 month ago
We hereby submit the Closure of Trading Window for iSEAR LifeSciences Limited (Formerly Known as Covidh Technologies Limited
1 month ago
We hereby submit the Closure of Trading Window for iSEAR LifeSciences Limited (Formerly Known as Covidh Technologies Limited
1 month ago
We hereby submit the copy of Newspaper Publication of Public Notice regarding 34th Annual General Meeting (AGM) of the Company scheduled to be held on Tuesday September 29 2026 at 3:00 P.M. (IST) through VC/ OAVM .
2 months ago
We hereby submit the copy of Newspaper Publication of Public Notice regarding 34th Annual General Meeting (AGM) of the Company scheduled to be held on Tuesday September 29 2026 at 3:00 P.M. (IST) through VC/ OAVM .
2 months ago
we hereby submit Annual Report of Annual General Meeting of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) for the financial year 2025-26
2 months ago
we hereby submit Annual Report of Annual General Meeting of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) for the financial year 2025-26
2 months ago
Notice of 34th Annual General Meeting (AGM) of the Company is scheduled to be held on Tuesday September 29 2026 at 3:00 P.M. (IST) through video conference (VC)/ other audio visual means (OAVM) in compliance with the applicable provisions of the Companies Act 2013 and rules made thereunder and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and relevant circulars issued by MCA and SEBI.
2 months ago
Notice of 34th Annual General Meeting (AGM) of the Company is scheduled to be held on Tuesday September 29 2026 at 3:00 P.M. (IST) through video conference (VC)/ other audio visual means (OAVM) in compliance with the applicable provisions of the Companies Act 2013 and rules made thereunder and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and relevant circulars issued by MCA and SEBI.
2 months ago
iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has filed with the exchange copy of newspaper publication.
2 months ago
iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has filed with the exchange copy of newspaper publication.
2 months ago
We hereby informed that Board of Directors of the Company at its meeting held on Tuesday the 01st September 2026 discuss the agenda attached herewith.
2 months ago
We hereby informed that Board of Directors of the Company at its meeting held on Tuesday the 01st September 2026 discuss the agenda attached herewith.
2 months ago
We hereby submit the monitoring Agency Report for utilization of proceeds of Rights Issue of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) for the quarter ended June 30 2026.
3 months ago
We are hereby submitting the Unaudited Financial Results of the Company for the quarter ended June 30 2026.
3 months ago
We are hereby submitting the Unaudited Financial Results of the Company for the quarter ended June 30 2026.
3 months ago
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations 2015 the Board of Directors of the Company at its meeting held on Friday the 07th day of August 2026 at the Registered Office of the Company which commenced at 02:00 P.M.and concluded at 02:30 P.M. considered and approved inter alia to approve the Un-Audited Financial Results of the Company for the quarter ended June 30 2026.
3 months ago

Concalls & investor presentations

Empty box

No presentations found

iSERA Lifesciences Ltd Share Price Today

The iSERA Lifesciences Ltd share price today is ₹143.9. During the trading session, the iSERA Lifesciences Ltd share price opened at ₹0 and recorded an intraday high of ₹0 and a low of ₹0. Last closing price was ₹143.9. Over the past 52 weeks, the iSERA Lifesciences Ltd share price has ranged between ₹7.99 and ₹151.05. The current iSERA Lifesciences Ltd stock price reflects real-time market activity based on executed trades on the exchange.